Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2016', provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) - The report reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Severe Acute Respiratory Syndrome (SARS) therapeutics and enlists all their major and minor projects - The report assesses Severe Acute Respiratory Syndrome (SARS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Severe Acute Respiratory Syndrome (SARS) Overview 8 Therapeutics Development 9 Pipeline Products for Severe Acute Respiratory Syndrome (SARS) - Overview 9 Pipeline Products for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis 10 Severe Acute Respiratory Syndrome (SARS) - Therapeutics under Development by Companies 11 Severe Acute Respiratory Syndrome (SARS) - Therapeutics under Investigation by Universities/Institutes 12 Severe Acute Respiratory Syndrome (SARS) - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Severe Acute Respiratory Syndrome (SARS) - Products under Development by Companies 15 Severe Acute Respiratory Syndrome (SARS) - Products under Investigation by Universities/Institutes 16 Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development 17 CEL-SCI Corporation 17 GeneCure LLC 18 Inovio Pharmaceuticals, Inc. 19 Nanotherapeutics, Inc. 20 Novavax, Inc. 21 Phelix Therapeutics, LLC 22 Planet Biotechnology Inc. 23 Protein Sciences Corporation 24 Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 32 Drug Profiles 34 CEL-1000 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 D-3252 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 FDX-000 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 INO-4500 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Middle East respiratory syndrome coronavirus vaccine - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ML-188 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Monoclonal Antibody for SARS Virus Infections - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 RBD-219N1 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 SARS (virus like particle) vaccine - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 severe acute respiratory syndrome vaccine - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 SSYA-10001 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Severe Acute Respiratory Syndrome (SARS) - Dormant Projects 50 Severe Acute Respiratory Syndrome (SARS) - Discontinued Products 53 Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones 54 Featured News & Press Releases 54 Oct 19, 2015: Inovio and Partner Advance MERS Vaccine 54 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016 9 Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corporation, H2 2016 17 Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H2 2016 18 Severe Acute Respiratory Syndrome (SARS) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 19 Severe Acute Respiratory Syndrome (SARS) - Pipeline by Nanotherapeutics, Inc., H2 2016 20 Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax, Inc., H2 2016 21 Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics, LLC, H2 2016 22 Severe Acute Respiratory Syndrome (SARS) - Pipeline by Planet Biotechnology Inc., H2 2016 23 Severe Acute Respiratory Syndrome (SARS) - Pipeline by Protein Sciences Corporation, H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Assessment by Combination Products, H2 2016 26 Number of Products by Stage and Target, H2 2016 28 Number of Products by Stage and Mechanism of Action, H2 2016 30 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2016 50 Severe Acute Respiratory Syndrome (SARS) - Dormant Projects (Contd..1), H2 2016 51 Severe Acute Respiratory Syndrome (SARS) - Dormant Projects (Contd..2), H2 2016 52 Severe Acute Respiratory Syndrome (SARS) - Discontinued Products, H2 2016 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.